Results 11 to 20 of about 1,680 (126)

Emicizumab prophylaxis in current haemophilia A care in the Czech Republic—data from the Czech National Haemophilia Programme Registry [PDF]

Research and Practice in Thrombosis and Haemostasis
Background: Nonfactor therapy with emicizumab has become an important part of the haemophilia A treatment landscape recently. Objectives: We aimed to analyze data on the transition from previous treatment regimens to emicizumab in routine clinical ...
Ester Zápotocká, Petra Ovesná, Bohumír Blažek, Zuzana Čermáková, Zdeňka Hajšmanová, Radomíra Hrdličková, Petr Birke, Daniela Procházková, Petr Smejkal, Jan Blatný   +9 more
doaj   +2 more sources

Modelling US health equity impacts of emicizumab for severe haemophilia A: aggregate distributional cost-effectiveness analysis [PDF]

BMJ Open
Objectives Emicizumab is the first bispecific antibody approved for prophylaxis in people with haemophilia A with or without factor VIII inhibitors. Aggregate distributional cost-effectiveness analysis assesses health equity impacts by evaluating how ...
Randall Curtis, Thomas Majda, Janet S. Lee, Stacey L. Kowal   +3 more
doaj   +2 more sources

Emicizumab Associated Rhabdomyolysis in Hemophilia A [PDF]

Clinical Hematology International, 2020
Emicizumab is increasingly the front-line treatment for patients with Hemophilia A with or without inhibitors. Rhabdomyolysis is a syndrome of muscle necrosis and release of intracellular muscle constituents into the circulation.
Joseph A. Wilson, Stephanie Hayden, Alexander Asamoah, Vivek R. Sharma, David C. Jennings, Ashok B. Raj   +5 more
doaj   +3 more sources

Lifetime Cost-Utility Analysis of Emicizumab Prophylaxis in Severe Haemophilia A Without Inhibitors in China: A Markov Model Analysis. [PDF]

Haemophilia
ABSTRACT Aim As emicizumab shares no sequence homology with factor VIII (FVIII), in patients with haemophilia A, haemostasis can be restored irrespective of the presence of FVIII inhibitors. Emicizumab, therefore, substantially improved previously available prophylactic options.
Bao H, Bührer C, Lin Z, Zhou L, Xia Y, Jin X, Xuan J.   +6 more
europepmc   +2 more sources

Outcomes of Emicizumab Treatment for Haemophilia A Paediatric Patients: A Systematic Review With Meta-Analysis. [PDF]

Haemophilia
ABSTRACT Introduction Haemophilia A in paediatric patients presents a lifelong risk of spontaneous and trauma‐induced haemorrhage, leading to progressive joint damage, disability and impaired quality of life. Emicizumab, a bispecific monoclonal antibody administered subcutaneously, offers sustained haemostatic protection and has shown promising ...
Bolou K, Triantafyllou G, Dettoraki A, Michalopoulou A, Kyprianou M, Papakonstantinou O, Pergantou H.   +6 more
europepmc   +2 more sources

A SIMULATION STUDY TO PROVIDE GUIDANCE FOR INDIVIDUALS TRANSITIONING FROM EMICIZUMAB TO VALOCTOCOGENE ROXAPARVOVEC

Hematology, Transfusion and Cell Therapy, 2023
Aim: Valoctocogene roxaparvovec (AAV5-hFVIII-SQ) is a gene therapy evaluated in the phase 3 GENEr8-1 trial that provides endogenous factor VIII (FVIII) production to prevent bleeding in people with severe hemophilia A and represents an alternative to ...
W Kuwabara, D Osmond, J Henshaw, S Agarwal, V Newman, C Hermans, W Miesbach, S Pipe, RS Jr, F Peyvandi   +9 more
doaj   +1 more source

Massive Intra-Abdominal Pseudotumor in a Patient With Hemophilia A Treated With Emicizumab: A Case Report. [PDF]

Clin Case Rep
ABSTRACT Hemophilic pseudotumors, a rare complication of bleeding disorders, are more common in settings with limited access to clotting factor concentrates. Subcutaneous emicizumab, a relatively novel therapy for hemophilia A, was investigated for its ability to stabilize an inoperable pseudotumor in a patient with factor VIII deficiency in an under ...
Kilach CJ, Njuguna C, Njuguna F, Wanjiku CM, Molitor KF, Janson IA, Mbunya SM, Shapiro AD, Sagar J, Greist A.   +9 more
europepmc   +2 more sources

Integration of Efanesoctocog Alfa in Clinical Practice for Children, Adolescents, and Young Adults With Severe Haemophilia A. [PDF]

Haemophilia
ABSTRACT Introduction Efanesoctocog alfa is a novel, “ultra‐extended half‐life” FVIII concentrate for bleed treatment and prevention in haemophilia A. Clinical trials excluded individuals with active or prior FVIII inhibitors, those on emicizumab, and previously untreated patients (PUPs).
Jiang D, Johnston N, Echelman D, Croteau SE.   +3 more
europepmc   +2 more sources

Differences in venous clot structures between hemophilic mice treated with emicizumab versus factor VIII or factor VIIIFc

Haematologica, 2023
Recombinant factor VIII (rFVIII), rFVIIIFc and emicizumab are established treatment options in the management of hemophilia A. Each has its unique mode of action, which can influence thrombin generation kinetics and therefore also the kinetics of ...
Thibaud Sefiane, Hortense Maynadié, Carmen Escurola Ettingshausen, Vincent Muczynski, Xavier Heiligenstein, Julien Dumont, Olivier D. Christophe, Cécile V. Denis, Caterina Casari, Peter J. Lenting   +9 more
doaj   +1 more source

The effect of emicizumab and bypassing agents in patients with hemophilia – An in vitro study

Research and Practice in Thrombosis and Haemostasis, 2021
Background Emicizumab is a nonfactor replacement therapy for hemophilia A (HA) and is a bispecific monoclonal antibody mimicking factor VIII by binding both factors IXa and X.
Nina Haagenrud Schultz, Heidi Glosli, Stine Bjørnsen, Pål Andre Holme   +3 more
doaj   +1 more source